Bromide

Bromide

SCHEMBL2396034

C=C[n+]1ccn(CCCCCCCCCCCCCCCC)c1.[Br-]

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.60
HSP90AA1 P07900 2/20 0.60
KMT2A Q03164 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
APAF1 O14727 1/20 0.60
NPC1 O15118 1/20 0.60
PLA2G1B P04054 1/20 0.60
MAPT P10636 1/20 0.60
MAPK1 P28482 1/20 0.60
HTT P42858 1/20 0.60
RAB9A P51151 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
ATG4B Q9Y4P1 1/20 0.60
FDPS P14324 17/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL2395819 1.00 MEN1 (0.60) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Bromide SCHEMBL2395832 1.00 MEN1 (0.60) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Bromide SCHEMBL2395867 1.00 MEN1 (0.60) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Bromide SCHEMBL2399324 1.00 MEN1 (0.60) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Bromide SCHEMBL2395677 1.00 MEN1 (0.60) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Bromide SCHEMBL2395709 1.00 MEN1 (0.60) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
SCHEMBL16307692 0.98 MEN1 (0.57) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
SCHEMBL31501079 0.98 MEN1 (0.57) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
SCHEMBL27921181 0.98 MEN1 (0.57) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
SCHEMBL8450143 0.98 MEN1 (0.57) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110527225-B Transparent high-electric-activity polyvinylidene fluoride-based composite material and preparation method thereof 长春工业大学 2021-07-30 CN claimed
WO-2013181345-A2 SYNTHESIS OF POLYMERIC IONIC LIQUIDS USING A PHOTOCHEMICAL POLYMERIZATION PROCESS THE UNIVERSITY OF TOLEDO (US) 2013-12-05 WO claimed
US-20110236295-A1 Polymeric Ionic Liquids, Methods of Making and Methods of Use Thereof UNIVERSITY OF TOLEDO (US) 2011-09-29 US claimed
WO-2010017563-A1 POLYMERIC IONIC LIQUIDS, METHODS OF MAKING AND METHODS OF USE THEREOF UNIVERSITY OF TOLEDO (US) 2010-02-11 WO claimed
US-20250135435-A1 SYSTEM FOR BATCH SCALE PRODUCTION OF EXTRACTION SORBENTS WITH 3D PRINTING AND ASSOCIATED METHOD OF USE IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 2025-05-01 US disclosed
CN-110527225-B Transparent high-electric-activity polyvinylidene fluoride-based composite material and preparation method thereof 长春工业大学 2021-07-30 CN disclosed
US-9837181-B2 Processes for nanoparticle dispersions with ionic liquid-based stabilizers EASTERN MICHIGAN UNIVERSITY (US) 2017-12-05 US disclosed
US-9782748-B2 Synthesis of polymeric ionic liquids using a photochemical polymerization process THE UNIVERSITY OF TOLEDO (US) 2017-10-10 US disclosed
US-9782746-B2 Polymeric ionic liquids, methods of making and methods of use thereof THE UNIVERSITY OF TOLEDO (US) 2017-10-10 US disclosed
US-20160114309-A1 Polymeric Ionic Liquids, Methods of Making and Methods of Use Thereof THE UNIVERSITY OF TOLEDO (US) 2016-04-28 US disclosed
US-9249261-B2 Polymeric ionic liquids, methods of making and methods of use thereof THE UNIVERSITY OF TOLEDO (US) 2016-02-02 US disclosed
US-20150119231-A1 Synthesis of Polymeric Ionic Liquids Using a Photochemical Polymerization Process THE UNIVERSITY OF TOLEDO (US) 2015-04-30 US disclosed
US-8920682-B2 Nanoparticle dispersions with ionic liquid-based stabilizers EASTERN MICHIGAN UNIVERSITY (US) 2014-12-30 US disclosed
US-8734673-B2 Boron selective ionic liquids and polymeric ionic liquids, methods of making and methods of use thereof THE UNIVERSITY OF TOLEDO (US) 2014-05-27 US disclosed
WO-2013181345-A2 SYNTHESIS OF POLYMERIC IONIC LIQUIDS USING A PHOTOCHEMICAL POLYMERIZATION PROCESS THE UNIVERSITY OF TOLEDO (US) 2013-12-05 WO disclosed
US-20120111796-A1 Boron Selective Ionic Liquids and Polymeric Ionic Liquids, Methods of Making and Methods of Use Thereof UNIVERSITY OF TOLEDO (US) 2012-05-10 US disclosed
US-20110233458-A1 Nanoparticle dispersions with ionic liquid-based stabilizers EASTERN MICHIGAN UNIVERSITY Office of Research Development (US) 2011-09-29 US disclosed
US-20110236295-A1 Polymeric Ionic Liquids, Methods of Making and Methods of Use Thereof UNIVERSITY OF TOLEDO (US) 2011-09-29 US disclosed
WO-2010017563-A1 POLYMERIC IONIC LIQUIDS, METHODS OF MAKING AND METHODS OF USE THEREOF UNIVERSITY OF TOLEDO (US) 2010-02-11 WO disclosed
WO-2010017564-A1 BORON SELECTIVE IONIC LIQUIDS AND POLYMERIC IONIC LIQUIDS, METHODS OF MAKING AND METHODS OF USE THEREOF UNIVERSITY OF TOLEDO (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120111796-A1 Boron Selective Ionic Liquids and Polymeric Ionic Liquids, Methods of Making and Methods of Use Thereof BCCIP, SLC6A12, BOLA2; BOLA2B MEN1 1196/4885HSP90AA1 4401/4885KMT2A 3451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.